FinnRick Lab Peptide Industry Data: Market Trends & Brand Comparison Analysis
Title: FinnRick Lab Peptide Industry Data: Market Trends & Brand Comparison Analysis Abstract: FinnRick Lab’s 2025 data reveals a 23.4% CAGR in global peptide therapeutics, driven by GLP-1 agonists and cosmetic peptides. Brand comparison shows Tier-1 manufacturers (e.g., Bachem, PolyPeptide) achieve >99% purity via HPLC-MS, while emerging brands offer cost advantages but lack FDA/DMF certifications. Key differentiators include lyophilization stability (≤2% moisture) and endotoxin levels (<0.5 EU/mg). Selection criteria prioritize third-party COA verification, cold-chain logistics (2–8°C), and batch-to-batch consistency. Industry trends indicate a shift toward personalized peptide cocktails and AI-driven synthesis, with regulatory compliance (cGMP, ISO 9001) becoming a market differentiator.